background: Vascular endothelial growth factor (VEGF) is the most potent stimulator of angiogenesis. It mediates its activity through two membrane-bound receptors, VEGFR-1 and VEGFR-2, both expressed in the placenta. Beginning in early pregnancy, the soluble form of the first, sVEGFR-1, binds and inhibits most of the biological actions of circulating VEGF. After delivery, it disappears from the maternal circulation.
Introduction
Vasculogenesis (de novo formation of new vessels) and angiogenesis (growth of new vessels sprouting from pre-existing ones) are essential in fetal development. During adulthood, angiogenesis is important especially in ovarian functions, endometrial maturation and placentation, as well as in tissue repair and wound healing. Pathologic angiogenesis is characterized as excessive or inadequate neovascularization. It is a crucial pathophysiological event in malignant, ischaemic, infectious, immune and inflammatory disorders (Carmeliet, 2005) . Angiogenesis is tightly regulated by a number of pro-and anti-angiogenic factors, and the vascular endothelial growth factor (VEGF) family plays a central role in this process.
The VEGF family comprises VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth factor (PlGF). Of these, VEGF-A, usually referred to as VEGF, is the most potent direct stimulator of vascular endothelial cell proliferation, survival and migration, and it also increases microvascular permeability (Ferrara et al., 2003; Hicklin and Ellis, 2005) . VEGF is known to be expressed by various normal tissues and tumours (Maharaj et al., 2006) . It is the main ligand for two endothelial cell membrane-bound receptors, VEGFR-1 (also referred to as fms-like tyrosine kinase-1) and VEGFR-2 (kinase insert domain-containing receptor). VEGFR-1 binds VEGF with high affinity, but it induces much weaker kinase activity than VEGFR-2. The latter mediates most of the endothelial growth and survival signals, while VEGFR-1 has been shown to have a dual role in angiogenesis (Shibuya, 2006) . First, during embryogenesis, it acts as a negative regulator of angiogenesis by trapping free VEGF and thereby suppressing the accessibility of VEGF for its other receptor, VEGFR-2, on the endothelial cell surface. Secondly, during adulthood, VEGFR-1 mediates paracrine signals on the endothelium, and on the other hand, it can stimulate tumour growth, metastasis and inflammation. Both of these VEGF-binding receptors have been shown to occur in soluble forms in human circulation (Banks et al., 1998; Ebos et al., 2004) .
Soluble VEGFR-1 (sVEGFR-1) is a splice variant of the membranebound VEGFR-1 only lacking its transmembrane and cytoplasmic domains (Kendall and Thomas, 1993) . Like the membrane-spanning form of the receptor, it binds VEGF-A, VEGF-B and PlGF, although the last one with much lower affinity than its main ligand, VEGF-A (Kendall and Thomas, 1993; Park et al., 1994) . Therefore, sVEGFR-1 serves as a potent inhibitor of the biological actions of VEGF and PlGF in two different ways: First, by binding VEGF it reduces the bioavailability of this pro-angiogenic factor for VEGFR-2 reducing its binding and the following downstream signalling via this main angiogenic route (Kendall and Thomas, 1993) . Second, sVEGFR-1 is able to heterodimerize with VEGFR-2 resulting in the blockade of the VEGFR-2-mediated signal transduction (Kendall et al., 1996) . Indeed, sVEGFR-1 has been described as a 'sink' for free VEGF (Hornig et al., 2000; Vuorela et al., 2000a,b) .
In human physiology the most remarkable scene for vasculo-and angiogenesis is the formation of the placenta and the fetus. Both VEGF and sVEGFR-1 are highly expressed in the placenta throughout pregnancy (Sharkey et al., 1993; Clark et al., 1996; Vuorela et al., 1997 Vuorela et al., , 2000a . sVEGFR-1 is released by early placental throphoblasts into maternal circulation where it can be detected as early as 30 days after conception (Molskness et al., 2004) . Later on, its concentrations increase rapidly with advancing pregnancy (Levine et al., 2004; McKeeman et al., 2004; Powers et al., 2005) . Meanwhile, the circulating concentrations of total VEGF increase as well (McKeeman et al., 2004) , but the concentration of the free, biologically active form declines in early pregnancy (Vuorela-Vepsalainen et al., 1999; Levine et al., 2004; Molskness et al., 2004) and remain mainly undetectable when assessed near term (Maynard et al., 2003; Tsatsaris et al., 2003; Levine et al., 2004; Wikstrom et al., 2007) . Following the first days after delivery free VEGF can again be detected in maternal circulation (Vuorela-Vepsalainen et al., 1999; Wikstrom et al., 2007) , indicating that its main binding protein, sVEGFR-1, disappears in the absence of the placenta.
As pregnancy is the only physiological state of remarkably high circulating sVEGFR-1 concentrations, and its main source, the placenta is eliminated at delivery, we investigated the elimination rate of endogenous sVEGFR-1 after delivery by elective Caesarean section in term pregnancy. In addition, this study aimed to elucidate the changes in sVEGFR-1 concentrations after legal termination of pregnancy, and the concurrent associated changes in free VEGF.
Materials and Methods
The study was approved by the Ethical Committee of Helsinki University Central Hospital. All women volunteered for the study and gave their written informed consent. They were healthy, non-smoking women with a singleton pregnancy. The study was conducted in two stages; we determined the elimination rate of sVEGFR-1 after an elective Caesarean section, and then we investigated the relationship between serum sVEGFR-1 and VEGF after a mid-trimester legal termination of pregnancy. hCG concentrations were measured to serve as reference for the half-life calculations.
Parturients undergoing elective Caesarean section
Eight women, aged 32 + 3 (mean + SD) years, who delivered by elective Caesarean sections at 40 + 0.4 weeks of gestation, were included in this study. A low level Caesarean section was performed in a uniform fashion for all of these women due to either breech presentation of the fetus, two or more previous Caesareans or fear of vaginal delivery.
Serial blood samples were taken before, during and after the Caesarean section as follows: the first sample was drawn after placing the patient in a supine position, the second one 15 min later, following pre-hydration and initiation of spinal anaesthesia, and the third one immediately before the start of the surgery. From then on, the next samples were collected at 15, 30, 60, 120, 180, 360 and 720 min. Additional daily samples were taken during the hospital stay (2-4 post-operative days).
For pre-medication, each woman received 30 ml of oral sodium citrate prior to entering the operation theatre in order to neutralize the gastric contents. Following the pre-hydration with 1000 ml of acetated Ringer's solution, spinal anaesthesia was induced using combined-spinal epidural technique with intrathecal administration of 8-9 mg of plain bupivacaine 0.5% (1.6-1.8 ml), 15 mg of fentanyl (0.3 ml) and 100 -160 mg of preservative-free morphine in saline (0.25 -0.4 ml). Oxygen was given at a rate of 4 l/min through a facial mask until delivery. A bolus of 5 IU of oxytocin was administered intravenously after delivery. Before the delivery of the fetus, three patients required 4 -6 ml epidural boluses of lidocaine (20 mg/ml) with epinephrine in order to supplement an insufficient level of the initial anaesthesia. In addition, four patients needed 5 -10 mg of ephedrine and one patient received a 50 mg bolus of phenylephrine in order to maintain adequate blood pressure. All women received a 500 ml gelatine infusion prior to delivery, after which they were given 1000 ml of acetated Ringer's solution and 500 ml of 5% glucose. Following the delivery of the fetus, two patients received 10 mg of metoclopramide for nausea and vomiting, six patients received a 25 mg bolus of pethidine to treat postoperative shivering, six patients received an oxytocin infusion (50 IU in 500 ml saline), two were treated with 800 mg of rectal misoprostol to avoid uterine atony and one patient was given a 4 mg bolus of ondansetron (5-HT 3 receptor antagonist) in order to prevent post-operative nausea. The mean peri-operative blood loss was 660 ml (range 300 -1200 ml).
Patients undergoing legal termination of pregnancy
Five women, aged 30 + 12 years, attending legal termination of pregnancy, participated in this study. They requested the abortion of their own will at 15 + 2 weeks of gestation. Two of them carried fetuses with trisomy 18 and one with trisomy 21, and two women requested the abortion because of socio-economical factors. Pregnancies were terminated surgically by uterine curettage. The first blood sample was taken 2 h before the vaginal administration of 200 mg of misoprostol, which was given to induce cervical ripening and contractions. The second sample was drawn at 1 h and the third one at 4 h after the beginning of contractions. The fourth sample was taken immediately prior to the curettage, counting from which the next blood samples were then collected at 5, 10, 15, 20, 30, 40, 60, 120, 180 , 360 and 720 min, and then every 24 h for the following 6 days. Additional blood samples were collected at 14 and 21 days following the operation. The curettage was uncomplicated in all women, and the estimated blood loss was 360 + 300 ml.
The blood samples from all women included in these studies were collected from the antecubital vein of the arm not used for infusions.
Blood was allowed to clot for 1 h at room temperature, after which serum was separated by centrifugation and stored at 2708C until analysis.
Laboratory methods
Commercially available enzyme-linked immunosorbent assays, ELISA (Quantikine w ; R&D Systems, Inc., Minneapolis, MN, USA), were used for determinations of VEGF and sVEGFR-1. The assay for VEGF detects only free VEGF, whereas that for sVEGFR-1 detects both sVEGFR-1 alone and the complexes with its ligands (VEGF-A, VEGF-B and PlGF). Only a small proportion of sVEGFR-1 has been shown to be complexed with its ligands (Vuorela-Vepsalainen et al., 1999; Belgore et al., 2001) , thus the concentration of free sVEGFR-1 does not greatly differ from the absolute total. Therefore, it was assumed that the calculated halflives also reflect those of free sVEGFR-1. Serum hCG was determined by a two-site immunofluorometric assay (Delfia w ; PerkinElmer-Wallac, Finland). The intra-and inter-assay coefficients of variation were 3.2 and 7.7% for sVEGFR-1, 5.0 and 8.2% for VEGF and 3.1 and 3.9% for hCG, respectively. The detection limits of the assays were 5 ng/l for sVEGFR-1 and VEGF, and 2 IU/l for hCG. Serial samples from each individual were analysed in the same batch. All determinations were done in duplicate and according to the manufacturer's instructions.
Statistical methods
Correlation between clinical characteristics and sVEGFR-1, VEGF or hCG concentrations preceding the operations was analysed using Pearson's correlation. Because the distribution of the cytokine concentrations was skewed, the comparison between serial samples was performed with the Wilcoxon signed-rank test, whereas the correlations between them were tested using Spearman's rank correlation. A two-tailed P-value , 0.05 was considered significant.
Calculation of half-lives
The half-lives for serum sVEGFR-1 after the elective Caesarean sections were estimated using a curve-fitting algorithm for multi-exponential decay by Microsoft Excel w . For interpreting the data, it was assumed that the observed concentrations of sVEGFR-1 consist of two exponentially decaying components, a rapid and a slow one, and a constant background. The data were fitted to the following function:
A(t) = a 1 e −(t ln 2/T1) + a 2 e −(t ln 2/T2) + a 3 such that a 1 and a 2 denote the amplitudes of the decaying components, a 3 the amplitude of the constant background, and T 1 and T 2 the corresponding half-lives. The fitting was performed using a usual least-square procedure varying the values of a 1 , a 2 , T 1 and T 2 . An initial attempt to fit three decaying components was made, but it did not produce reliable results and therefore it was not applied. In this procedure, each measurement point was given with the same weight. The question of assigning proper weights is complicated as the readings are not simple functions of any primary signal with a uniquely known standard deviation. However, extensive empirical evidence from these kinds of measurements suggests that an equal weight is a reasonable choice, because the apparatus largely determines the noise in the signal. We used various other choices of weight, but they did not affect the obtained values to any appreciable extent considering the variation among different patients. The background was set at 50 ng/l for sVEGFR-1 and 10 IU/l for hCG as numerical checks showed that these assumptions are quite robust since other reasonable values did not produce appreciable changes in the half-lives. The samples with an elevating sVEGFR-1 concentration, taken shortly after the beginning of the operation, were not used in the half-life calculations so that the concentrations would settle properly on the exponential decay.
Results

Disappearance of sVEGFR-1 after elective Caesarean section
Before the Caesarean section the median circulating sVEGFR-1 concentration was 11 180 ng/l (6380-17 480 ng/l, range). The initial sVEGFR-1 (and hCG) concentrations and the clinical characteristics of the parturients were independent from each other (data not shown). After premedication, initiation of anaesthesia and pre-hydration, the median sVEGFR-1 concentration was 9630 ng/l (5850-14 950 ng/l) and 15 min later, at the beginning of the operation, it was 11 570 ng/l (5850-14 950 ng/l) from where it further increased by 20% (8-47%) at 30 min (18-72 min) in six of the patients (P ¼ 0.028; Wilcoxon signed-rank test), and a similar rise was also seen in the two other patients after the next sampling. At its highest, the concentration of sVEGFR-1 was 15 390 ng/l (6910-17 680 ng/l). However, there was no simultaneous increase in serum hCG. We therefore calculated half-lives of sVEGFR-1 after this initial increase. The disappearance of sVEGFR-1 was best described as biphasic, although there was a large variation between the half-lives of individual patients. The median halflife of the first phase (rapid) was 3.4 h (2.2 -7.5 h), whereas that of the second phase (slow) was 29 h (17-94 h; Table I ). The representative exponential curves showing the two half-lives of sVEGFR-1 in one of the patients (Patient 6) are shown in Fig. 1 . The half-lives of sVEGFR-1 were quite similar to those of hCG (Table I) The elimination of sVEGFR-1 was biphasic and the half-lives were calculated using a curve-fitting algorithm showing two exponentially decaying components, a rapid and a slow one. The half-lives are expressed in hours. sVEGFR-1, soluble vascular endothelial growth factor receptor-1; hCG, human chorionic gonadotrophin.
components of hCG did (r ¼ 0.76, P ¼ 0.028; Spearman's rank correlation).
Sequential changes in sVEGFR-1 and VEGF concentrations after legal termination of pregnancy
Before the administration of misoprostol, the median serum concentration of sVEGFR-1 was 1000 ng/l (200-1430 ng/l) and that of free VEGF was 21 ng/l (14 -28 ng/l). After the beginning of contractions, the sVEGFR-1 concentration increased by 25% (12 -29%) at 1 h (1250 ng/l, 200 -1840 ng/l; P ¼ 0.043, Wilcoxon signed-rank test), whereas those of VEGF remained stable. A similar rise in sVEGFR-1 concentrations was also seen after the initiation of Caesarean section (see above). After the termination of pregnancy, the concentrations of sVEGFR-1 decreased, while those of free VEGF increased, with a significant negative correlation with each other (r ¼ 20.90, P , 0.0001; Spearman's rank correlation; Fig. 2 ). The concentrations of VEGF reached a constant level (130 ng/l, 24 -246 mg/l) between the 3rd and 6th day and those of sVEGFR-1 in 6 days (83 ng/l, 26-256 ng/l) after the curettage.
Discussion
We studied the disappearance of endogenous sVEGFR-1 after elective Caesarean sections and changes between serum sVEGFR-1 and VEGF concentrations after legal termination of pregnancy. Caesarean section facilitates evaluation of the elimination rate of endogenous sVEGFR-1 since its circulating concentrations during pregnancy are much higher than in non-pregnant women, and its main source, the placenta, is rapidly removed. This setting has some limitations, e.g. fluid infusion before surgery caused a decrease in sVEGFR-1 concentrations, after which there was a transient increase in the circulating sVEGFR-1 following the beginning of the Caesarean section. This increase is probably due to manipulation of the placenta, containing remarkable amounts of sVEGFR-1. However, if the delay before starting the fitting procedure is sufficiently long, the transient is attenuated and does not affect the estimate of the half-life. As a reference we measured serum hCG concentrations and observed a fairly wide range in the half-lives also for this protein. After the initial increase of serum sVEGFR-1, its disappearance curve was biphasic, and the calculated half-lives were similar to those of hCG observed in both the present and a previous study (Korhonen et al., 1997) . Biphasic elimination is typical for proteins. It is probably attributable to a rapid initial phase caused by a clearance from the intravascular space followed by a slower phase reflecting removal of the protein from the extravascular space. The route of elimination for sVEGFR-1 is not known, but based on its molecular size, 110 kDa (Kendall and Thomas, 1993) , it is likely to be mainly removed by the liver and/or the reticuloendothelial system. It has been assumed that sVEGFR-1 is the predominant regulator of the bioavailability of circulating VEGF, although other soluble receptors in the VEGF family, sVEGFR-2 and soluble neuropilin-1 (sNRP-1), may also contribute to this regulation (Gagnon et al., 2000; Ebos et al., 2004) . Furthermore, sVEGFR-1 itself has additional ligand partners: Figure 2 The decrease in serum concentrations of sVEGFR-1 in five pregnant women after legal termination of pregnancy at 15 + 2 (mean + SD) weeks of gestation is associated with a simultaneous increase in free VEGF concentrations with a significant negative correlation with each other (r ¼ 20.90, P , 0.0001; Spearman's rank correlation). The median VEGF concentration reached a constant level between the 3rd and 6th day and that of sVEGFR-1 in 6 days after the curettage. Figure 1 The half-lives of sVEGFR-1 were estimated in serum of eight healthy pregnant women after elective Caesarean sections using a curve-fitting algorithm for multi-exponential decay (Microsoft Excel). For the calculations, it was assumed that the observed concentrations of sVEGFR-1 consist of two exponentially decaying components, a rapid and a slow one, and a constant background. The equation used for the fitting procedure is shown in the Methods. The figure represents the exponential curves showing the biphasic elimination of sVEGFR-1 in one of the patients with an individual rapid half-life of 7.5 h and a slow half-life of 49 h. After the initial increase during the operation, her sVEGFR-1 concentration was 13 050 ng/l from where on the half-lives were then calculated.
besides VEGF-A it also binds VEGF-B and PlGF. However, it has been suggested that only a minor part of the total sVEGFR-1 in circulation is complexed with its ligands (Vuorela-Vepsalainen et al., 1999; Belgore et al., 2001) . During pregnancy, the concentrations of free VEGF are low (Vuorela-Vepsalainen et al., 1999; Levine et al., 2004; Molskness et al., 2004) , which has been suggested to be due to its binding to sVEGFR-1. This notion is further supported by our results which indicate a strong negative correlation between the serum concentrations of sVEGFR-1 and free VEGF after legal termination of pregnancy. Earlier studies have measured circulating sVEGFR-1 concentrations post-partum especially in connection with the common pregnancy complication pre-eclampsia, in which the antenatal sVEGFR-1 concentrations are much higher than in uncomplicated pregnancies (Koga et al., 2003; Maynard et al., 2003; Levine et al., 2004; Powers et al., 2005; Wikstrom et al., 2007) . This excess in circulating sVEGFR-1 is suggested to originate from the placenta as its concentrations decline rapidly during the first week after delivery, also following uncomplicated pregnancies (Koga et al., 2003; Maynard et al., 2003; Powers et al., 2005; Wikstrom et al., 2007) . The sVEGFR-1 concentrations have been shown to decrease within 48 h after delivery (Maynard et al., 2003) and calculated to decline by 2.5% per hour in another study (based on a sample taken at delivery and another one within 48 h) (Powers et al., 2005) . However, half-lives of endogenous sVEGFR-1 have not been measured before. Furthermore, the blood concentrations of free VEGF increase post-partum possibly as a result of the disappearance of its binding protein, sVEGFR-1 (Vuorela-Vepsalainen et al., 1999; Wikstrom et al., 2007) . Our results confirm that there is an excess of sVEGFR-1 during pregnancy, but soon after delivery the concentrations of free VEGF in circulation exceed those of sVEGFR-1.
Angiogenesis is essential for tumour growth and metastasis, and the balance between pro-and anti-angiogenic factors regulates this process. As the VEGF family plays a central role in tumour angiogenesis, the blockade of this pathway is a promising therapeutic strategy for inhibition of tumour growth (Carmeliet, 2005; Hicklin and Ellis, 2005; Folkman, 2007) . In addition, some endogenous anti-angiogenic factors, also of potential therapeutic use, have been identified (Folkman, 2004) . The first VEGF-antagonists, approved for clinical use several years ago, were antibodies against human VEGF, and subsequently many other anti-angiogenic drugs have been introduced. Anti-VEGF therapy can be based on targeting of either the molecule or its receptors, the use of ribozymes to decrease receptor expression or inhibitors of tyrosine kinase to block receptor activation (Folkman, 2007; Chu, 2009 ). Interestingly, VEGF-blocking therapy has side effects resembling the symptoms of pre-eclampsia, i.e. hypertension, proteinuria and oedema, suggesting that related mechanisms are involved (Chu, 2009; Launay-Vacher and Deray, 2009 ). Thus, information on the kinetics of endogenous sVEGFR-1, acting as a naturally occurring inhibitor of VEGF, might also be valuable for studies on this angiogenesis-associated pregnancy complication.
In conclusion, the disappearance of endogenous sVEGFR-1 after Caesarean delivery is biphasic comprising a rapid half-life of 3.4 h and a slow one of 29 h. After mid-trimester legal termination of pregnancy, the concentrations of sVEGFR-1 decrease simultaneously with an increase in free VEGF concentrations. Our results provide information on the kinetics of endogenous sVEGFR-1 which is of potential utility in the development of new therapeutic tools.
